<DOC>
	<DOCNO>NCT00693342</DOCNO>
	<brief_summary>RATIONALE : Vaccines make tumor antigen may help body build effective immune response kill tumor cell . Biological therapy , OPT-821 , may stimulate immune system different way stop tumor cell grow . Giving vaccine therapy together OPT-821 may kill tumor cell . It yet know whether give vaccine therapy together OPT-821 effective OPT-821 alone treat ovarian epithelial cancer , fallopian tube cancer , primary peritoneal cancer . PURPOSE : This randomized phase III trial study vaccine therapy OPT-821 see well work compare OPT-821 alone treat patient ovarian epithelial cancer , fallopian tube cancer , primary peritoneal cancer complete remission .</brief_summary>
	<brief_title>Vaccine Therapy OPT-821 OPT-821 Alone Treating Patients With Ovarian Epithelial Cancer , Fallopian Tube Cancer , Primary Peritoneal Cancer Complete Remission</brief_title>
	<detailed_description>OBJECTIVES : Primary - To compare progression-free survival patient ovarian epithelial , fallopian tube , primary peritoneal cancer second third complete clinical remission treat polyvalent antigen-KLH conjugate vaccine ( GM2-KLH , Globo-H-KLH , Tn-MUC1-32mer-KLH , TF-KLH , sTn-KLH ) combination OPT-821 vs OPT-821 alone . Secondary - To compare incidence toxicity patient treat regimen . - To compare overall survival patient treat regimen . - To characterize immune response ( ELISA ) limit sample patient , order determine outcome correlate antigen-specific immune titer . OUTLINE : This multicenter study . Patients randomize 1 2 treatment arm . - Arm I : Patients receive polyvalent antigen-KLH conjugate vaccine combination OPT-821 subcutaneously ( SC ) week 1 , 2 , 3 , 7 , 15 , 27 , 39 , 51 , 63 , 75 , 87 . - Arm II : Patients receive OPT-821 SC week 1 , 2 , 3 , 7 , 15 , 27 , 39 , 51 , 63 , 75 , 87 . Patients undergo blood sample collection periodically correlative study . Samples analyze antibody expression antigen ( i.e. , Tn-MUC1-32mer , GM2 , Globo-H , TF , sTN , Tn ) ELISA . IgM IgG titer also measure . After completion study treatment , patient follow every 3 month 2 year , every 6 month 3 year , annually thereafter .</detailed_description>
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<mesh_term>Peritoneal Neoplasms</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Adjuvants , Immunologic</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm ovarian epithelial , fallopian tube , primary peritoneal cancer Any stage grade diagnosis allow Has undergone initial cytoreductive surgery receive least one platinumbased chemotherapy regimen Recurred initial therapy , second third complete clinical remission define follow : Serum CA125 normal Negative physical examination No definitive evidence disease CT scan abdomen pelvis ( lymph node and/or soft tissue abnormality ≤ 1.0 cm consider definitive evidence disease ) A positive PET scan allow provide criterion meet MRI CT scan negative Completed last course chemotherapy within past 4 month PATIENT CHARACTERISTICS : GOG performance status 02 Absolute neutrophil count ≥ 1,000/mm³ Platelet count ≥ 100,000/mm³ Serum creatinine ≤ 1.5 time upper limit normal ( ULN ) Bilirubin ≤ 2.0 time ULN SGOT ≤ 2.0 time ULN Alkaline phosphatase ≤ 2.0 time ULN PRIOR CONCURRENT THERAPY : See Disease Characteristics</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2008</verification_date>
	<keyword>stage IA primary peritoneal cavity cancer</keyword>
	<keyword>stage IB primary peritoneal cavity cancer</keyword>
	<keyword>stage IC primary peritoneal cavity cancer</keyword>
	<keyword>stage IIA primary peritoneal cavity cancer</keyword>
	<keyword>stage IIB primary peritoneal cavity cancer</keyword>
	<keyword>stage IIC primary peritoneal cavity cancer</keyword>
	<keyword>stage IIIA primary peritoneal cavity cancer</keyword>
	<keyword>stage IIIB primary peritoneal cavity cancer</keyword>
	<keyword>stage IIIC primary peritoneal cavity cancer</keyword>
	<keyword>stage IV primary peritoneal cavity cancer</keyword>
	<keyword>stage IA fallopian tube cancer</keyword>
	<keyword>stage IB fallopian tube cancer</keyword>
	<keyword>stage IC fallopian tube cancer</keyword>
	<keyword>stage IIA fallopian tube cancer</keyword>
	<keyword>stage IIB fallopian tube cancer</keyword>
	<keyword>stage IIC fallopian tube cancer</keyword>
	<keyword>stage IIIA fallopian tube cancer</keyword>
	<keyword>stage IIIB fallopian tube cancer</keyword>
	<keyword>stage IIIC fallopian tube cancer</keyword>
	<keyword>stage IV fallopian tube cancer</keyword>
	<keyword>stage IA ovarian epithelial cancer</keyword>
	<keyword>stage IB ovarian epithelial cancer</keyword>
	<keyword>stage IC ovarian epithelial cancer</keyword>
	<keyword>stage IIA ovarian epithelial cancer</keyword>
	<keyword>stage IIB ovarian epithelial cancer</keyword>
	<keyword>stage IIC ovarian epithelial cancer</keyword>
	<keyword>stage IIIA ovarian epithelial cancer</keyword>
	<keyword>stage IIIB ovarian epithelial cancer</keyword>
	<keyword>stage IIIC ovarian epithelial cancer</keyword>
	<keyword>stage IV ovarian epithelial cancer</keyword>
</DOC>